Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...